Incyte Co. (NASDAQ:INCY) Shares Sold by Mather Group LLC.

Mather Group LLC. lessened its stake in Incyte Co. (NASDAQ:INCY) by 70.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 655 shares of the biopharmaceutical company’s stock after selling 1,533 shares during the quarter. Mather Group LLC.’s holdings in Incyte were worth $43,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in INCY. Wellington Management Group LLP increased its holdings in Incyte by 48.8% in the fourth quarter. Wellington Management Group LLP now owns 131,649 shares of the biopharmaceutical company’s stock valued at $8,266,000 after buying an additional 43,160 shares during the last quarter. Fulton Bank N.A. purchased a new position in shares of Incyte in the 1st quarter valued at about $1,425,000. FORVIS Wealth Advisors LLC acquired a new stake in shares of Incyte during the 1st quarter worth about $1,495,000. ProShare Advisors LLC lifted its stake in Incyte by 14.4% during the first quarter. ProShare Advisors LLC now owns 63,086 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 7,925 shares during the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in Incyte in the first quarter valued at approximately $463,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Incyte

In related news, insider Thomas Tray sold 572 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the sale, the insider now owns 24,825 shares of the company’s stock, valued at approximately $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Incyte news, insider Thomas Tray sold 572 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.94, for a total transaction of $36,001.68. Following the sale, the insider now directly owns 24,825 shares in the company, valued at approximately $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vijay K. Iyengar sold 15,571 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $70.00, for a total value of $1,089,970.00. Following the completion of the sale, the executive vice president now directly owns 36,701 shares in the company, valued at $2,569,070. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,899 shares of company stock valued at $1,736,746 in the last ninety days. 17.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

INCY has been the topic of a number of research analyst reports. BMO Capital Markets reissued an “underperform” rating and set a $48.00 price objective (down previously from $52.00) on shares of Incyte in a report on Tuesday, July 2nd. Truist Financial reissued a “hold” rating and issued a $74.00 price target (down from $83.00) on shares of Incyte in a research report on Wednesday, September 18th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a report on Monday, September 16th. Royal Bank of Canada reissued a “sector perform” rating and issued a $67.00 target price on shares of Incyte in a report on Tuesday, September 3rd. Finally, Bank of America raised their price target on Incyte from $66.00 to $68.00 and gave the stock a “neutral” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $73.21.

Incyte Price Performance

Shares of INCY opened at $66.12 on Monday. The company has a current ratio of 1.92, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $64.30 and its two-hundred day moving average is $60.59. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $70.36. The firm has a market capitalization of $14.85 billion, a PE ratio of 20.04, a P/E/G ratio of 5.30 and a beta of 0.73.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The firm’s quarterly revenue was up 9.3% compared to the same quarter last year. Research analysts anticipate that Incyte Co. will post 0.66 earnings per share for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.